Arima Genomics Appoints Genomics Veteran as CEO
Deal News | Jun 16, 2025 | Illumina Ventures
Arima Genomics, a company specializing in genomic research, has appointed Tom Willis, a well-known figure in the genomics industry, as its Chief Executive Officer. This strategic decision coincides with the closure of a $22 million Series C financing round led by Illumina Ventures. This funding will catalyze Arima’s clinical expansion efforts, enhancing their position in the genomics sector. Illumina Ventures is known for investing in promising biotechnology companies, and their involvement signifies a vote of confidence in Arima Genomics' innovative capabilities and future potential.
Sectors
- Biotechnology
- Venture Capital & Private Equity
Geography
- United States – Arima Genomics and Illumina Ventures are likely based in the United States, which is a central hub for biotechnology and venture capital activities.
Industry
- Biotechnology – The article involves Arima Genomics, a company operating within the biotechnology sector, focusing on genomic research.
- Venture Capital & Private Equity – Illumina Ventures, a Venture Capital firm, is leading the Series C funding, indicating activity within the private equity and venture capital industry.
Financials
- $22 Million – The amount secured in Series C financing led by Illumina Ventures.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Arima Genomics | Target Company | Company | A genomics research company working on clinical expansion. |
| Illumina Ventures | Lead Investor | PE Firm | A venture capital firm investing in genomics and biotechnology companies. |
| Tom Willis | New CEO | Person | Recently appointed Chief Executive Officer of Arima Genomics and a veteran in the genomics industry. |